Trial Profile

A Phase 2 Study of APX005M in Combination With Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sotigalimab (Primary) ; Carboplatin; Paclitaxel
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use
Sponsors Apexigen

18 Jul 2023 Status changed from active, no longer recruiting to completed.
19 Jan 2023 According to an Apexigen media release, results from this trial will be presented at the ASCO Gastrointestinal Cancers Symposium 2023.
13 Sep 2022 Results assessing safety and efficacy of combining sotiga with neoadjuvant chemoradiation in patients with esophageal/gastroesophageal junction cancers, presented at the 47th European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com